View ValuationCorline Biomedical 향후 성장Future 기준 점검 2/6Corline Biomedical의 수익이 증가할 것으로 예상됨입니다.핵심 정보n/a이익 성장률n/aEPS 성장률Pharmaceuticals 이익 성장35.3%매출 성장률47.3%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트11 May 2026최근 향후 성장 업데이트Price Target Changed • Feb 18Price target decreased by 12% to kr29.00Down from kr33.00, the current price target is provided by 1 analyst. New target price is 90% above last closing price of kr15.30. Stock is up 46% over the past year. The company posted a net loss per share of kr1.06 last year.Price Target Changed • Sep 02Price target increased by 14% to kr21.00Up from kr18.50, the current price target is provided by 1 analyst. New target price is 48% above last closing price of kr14.20. Stock is up 61% over the past year. The company posted a net loss per share of kr1.06 last year.Price Target Changed • Jun 30Price target increased by 30% to kr39.00Up from kr30.00, the current price target is provided by 1 analyst. New target price is 174% above last closing price of kr14.25. Stock is up 46% over the past year. The company is forecast to post a net loss per share of kr0.03 compared to earnings per share of kr0.11 last year.Breakeven Date Change • May 19Forecast breakeven date pushed back to 2024The analyst covering Corline Biomedical previously expected the company to break even in 2023. New forecast suggests losses will reduce by 46% per year to 2023. The company is expected to make a profit of kr116.0m in 2024. Average annual earnings growth of 119% is required to achieve expected profit on schedule.모든 업데이트 보기Recent updates분석 기사 • May 11We Think Corline Biomedical (STO:CLBIO) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Reported Earnings • Apr 26Full year 2025 earnings released: kr0.59 loss per share (vs kr1.06 loss in FY 2024)Full year 2025 results: kr0.59 loss per share (improved from kr1.06 loss in FY 2024). Revenue: kr8.59m (down 50% from FY 2024). Net loss: kr14.7m (loss narrowed 37% from FY 2024). Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 106 percentage points per year, which is a significant difference in performance.공시 • Apr 08Corline Biomedical AB, Annual General Meeting, May 12, 2026Corline Biomedical AB, Annual General Meeting, May 12, 2026, at 15:00 W. Europe Standard Time. Location: premises of advokatfirman lindahl, vaksalagatan 10, uppsala SwedenRecent Insider Transactions • Feb 20Chief Executive Officer recently bought kr145k worth of stockOn the 17th of February, Henrik Nittmar bought around 10k shares on-market at roughly kr14.54 per share. This transaction amounted to 1.6% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Henrik has been a buyer over the last 12 months, purchasing a net total of kr377k worth in shares.Reported Earnings • Feb 19Full year 2025 earnings released: kr0.59 loss per share (vs kr1.06 loss in FY 2024)Full year 2025 results: kr0.59 loss per share (improved from kr1.06 loss in FY 2024). Revenue: kr8.62m (down 50% from FY 2024). Net loss: kr14.7m (loss narrowed 37% from FY 2024). Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 105 percentage points per year, which is a significant difference in performance.Price Target Changed • Feb 18Price target decreased by 12% to kr29.00Down from kr33.00, the current price target is provided by 1 analyst. New target price is 90% above last closing price of kr15.30. Stock is up 46% over the past year. The company posted a net loss per share of kr1.06 last year.New Risk • Jan 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 19% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Revenue is less than US$1m (kr8.9m revenue, or US$963k). Minor Risks Shareholders have been diluted in the past year (19% increase in shares outstanding). Market cap is less than US$100m (kr466.2m market cap, or US$50.5m).Reported Earnings • Nov 19Third quarter 2025 earnings released: kr0.14 loss per share (vs kr0.14 loss in 3Q 2024)Third quarter 2025 results: kr0.14 loss per share. Revenue: kr1.61m (down 41% from 3Q 2024). Net loss: kr3.36m (loss widened 12% from 3Q 2024). Revenue is forecast to grow 68% p.a. on average during the next 3 years, compared to a 27% growth forecast for the Pharmaceuticals industry in Sweden.Price Target Changed • Sep 02Price target increased by 14% to kr21.00Up from kr18.50, the current price target is provided by 1 analyst. New target price is 48% above last closing price of kr14.20. Stock is up 61% over the past year. The company posted a net loss per share of kr1.06 last year.Reported Earnings • Aug 27Second quarter 2025 earnings released: kr0.13 loss per share (vs kr0.20 loss in 2Q 2024)Second quarter 2025 results: kr0.13 loss per share (improved from kr0.20 loss in 2Q 2024). Revenue: kr2.63m (down 60% from 2Q 2024). Net loss: kr3.26m (loss narrowed 26% from 2Q 2024). Revenue is forecast to grow 55% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 119 percentage points per year, which is a significant difference in performance.New Risk • Aug 04New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr23m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-kr23m free cash flow). Minor Risks Revenue is less than US$5m (kr14m revenue, or US$1.4m). Market cap is less than US$100m (kr315.9m market cap, or US$32.7m).Reported Earnings • May 09First quarter 2025 earnings released: kr0.13 loss per share (vs kr0.078 loss in 1Q 2024)First quarter 2025 results: kr0.13 loss per share (further deteriorated from kr0.078 loss in 1Q 2024). Revenue: kr2.23m (down 60% from 1Q 2024). Net loss: kr3.07m (loss widened 84% from 1Q 2024). Revenue is forecast to grow 46% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 88 percentage points per year, which is a significant difference in performance.공시 • Apr 10Corline Biomedical AB, Annual General Meeting, May 15, 2025Corline Biomedical AB, Annual General Meeting, May 15, 2025, at 10:00 W. Europe Standard Time. Location: at the premises of advokatfirman lindahl, vaksalagatan 10 in uppsala, uppsala SwedenReported Earnings • Feb 18Full year 2024 earnings: EPS and revenues miss analyst expectationsFull year 2024 results: kr1.06 loss per share (further deteriorated from kr0.084 loss in FY 2023). Revenue: kr17.7m (down 50% from FY 2023). Net loss: kr23.2m (loss widened kr21.4m from FY 2023). Revenue missed analyst estimates by 30%. Earnings per share (EPS) also missed analyst estimates. Revenue is forecast to grow 44% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.Board Change • Feb 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Non-Executive Director Tomas Lifvendahl was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Nov 08Third quarter 2024 earnings released: kr0.14 loss per share (vs kr0.008 profit in 3Q 2023)Third quarter 2024 results: kr0.14 loss per share (down from kr0.008 profit in 3Q 2023). Revenue: kr2.76m (down 66% from 3Q 2023). Net loss: kr3.00m (down kr3.18m from profit in 3Q 2023). Revenue is forecast to grow 103% p.a. on average during the next 3 years, compared to a 32% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings.Reported Earnings • Aug 25Second quarter 2024 earnings released: kr0.20 loss per share (vs kr0.11 loss in 2Q 2023)Second quarter 2024 results: kr0.20 loss per share (further deteriorated from kr0.11 loss in 2Q 2023). Revenue: kr6.55m (down 24% from 2Q 2023). Net loss: kr4.37m (loss widened 82% from 2Q 2023). Revenue is forecast to grow 77% p.a. on average during the next 3 years, compared to a 39% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.분석 기사 • Aug 24Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its BusinessJust because a business does not make any money, does not mean that the stock will go down. For example, although...Reported Earnings • May 05First quarter 2024 earnings released: kr0.078 loss per share (vs kr0.047 profit in 1Q 2023)First quarter 2024 results: kr0.078 loss per share (down from kr0.047 profit in 1Q 2023). Revenue: kr5.64m (down 45% from 1Q 2023). Net loss: kr1.67m (down 264% from profit in 1Q 2023). Revenue is forecast to grow 68% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.New Risk • May 03New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr9.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-kr9.7m free cash flow). Minor Risks Revenue is less than US$5m (kr36m revenue, or US$3.3m). Market cap is less than US$100m (kr226.7m market cap, or US$20.9m).분석 기사 • Mar 15We Think Corline Biomedical (STO:CLBIO) Can Afford To Drive Business GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, although...Reported Earnings • Feb 16Full year 2023 earnings released: kr0.084 loss per share (vs kr0.11 profit in FY 2022)Full year 2023 results: kr0.084 loss per share (down from kr0.11 profit in FY 2022). Revenue: kr35.9m (up 10% from FY 2022). Net loss: kr1.81m (down 178% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.공시 • Jan 31+ 1 more updateCorline Biomedical AB to Report Nine Months, 2024 Results on Nov 07, 2024Corline Biomedical AB announced that they will report nine months, 2024 results on Nov 07, 2024공시 • Nov 03Corline Biomedical AB to Report Q1, 2024 Results on Apr 30, 2024Corline Biomedical AB announced that they will report Q1, 2024 results on Apr 30, 2024Reported Earnings • Aug 28Second quarter 2023 earnings released: kr0.11 loss per share (vs kr0.041 profit in 2Q 2022)Second quarter 2023 results: kr0.11 loss per share (down from kr0.041 profit in 2Q 2022). Revenue: kr8.60m (up 20% from 2Q 2022). Net loss: kr2.41m (down 375% from profit in 2Q 2022). Revenue is forecast to grow 46% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.New Risk • Jul 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). High level of non-cash earnings (30% accrual ratio). Minor Risks Revenue is less than US$5m (kr38m revenue, or US$3.5m). Market cap is less than US$100m (kr306.2m market cap, or US$28.3m).Price Target Changed • Jun 30Price target increased by 30% to kr39.00Up from kr30.00, the current price target is provided by 1 analyst. New target price is 174% above last closing price of kr14.25. Stock is up 46% over the past year. The company is forecast to post a net loss per share of kr0.03 compared to earnings per share of kr0.11 last year.Valuation Update With 7 Day Price Move • May 05Investor sentiment improves as stock rises 31%After last week's 31% share price gain to kr13.75, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 17x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 34% over the past three years.Reported Earnings • Apr 18Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: EPS: kr0.11 (up from kr0.34 loss in FY 2021). Revenue: kr32.6m (up 90% from FY 2021). Net income: kr2.33m (up kr9.25m from FY 2021). Profit margin: 7.1% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 12%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.공시 • Jan 13+ 4 more updatesCorline Biomedical AB to Report First Half, 2023 Results on Aug 25, 2023Corline Biomedical AB announced that they will report first half, 2023 results on Aug 25, 2023Reported Earnings • Nov 27Third quarter 2022 earnings released: EPS: kr0.091 (vs kr0.097 loss in 3Q 2021)Third quarter 2022 results: EPS: kr0.091 (up from kr0.097 loss in 3Q 2021). Revenue: kr11.0m (up 275% from 3Q 2021). Net income: kr1.97m (up kr4.04m from 3Q 2021). Profit margin: 18% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. Revenue is forecast to grow 97% p.a. on average during the next 3 years, compared to a 33% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.분석 기사 • Nov 26We're Interested To See How Corline Biomedical (STO:CLBIO) Uses Its Cash Hoard To GrowEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Reported Earnings • Aug 28Second quarter 2022 earnings released: EPS: kr0.041 (vs kr0.10 loss in 2Q 2021)Second quarter 2022 results: EPS: kr0.041 (up from kr0.10 loss in 2Q 2021). Revenue: kr7.31m (up 117% from 2Q 2021). Net income: kr875.0k (up kr3.03m from 2Q 2021). Profit margin: 12% (up from net loss in 2Q 2021). The move to profitability was driven by higher revenue. Over the next year, revenue is forecast to grow 39%, compared to a 90% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.분석 기사 • Jun 22Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its BusinessJust because a business does not make any money, does not mean that the stock will go down. For example, although...Breakeven Date Change • May 19Forecast breakeven date pushed back to 2024The analyst covering Corline Biomedical previously expected the company to break even in 2023. New forecast suggests losses will reduce by 46% per year to 2023. The company is expected to make a profit of kr116.0m in 2024. Average annual earnings growth of 119% is required to achieve expected profit on schedule.Reported Earnings • May 16First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: kr0.04 loss per share (up from kr0.08 loss in 1Q 2021). Revenue: kr4.53m (up 65% from 1Q 2021). Net loss: kr852.0k (loss narrowed 39% from 1Q 2021). Revenue exceeded analyst estimates by 41%. Earnings per share (EPS) also surpassed analyst estimates by 15%. Over the next year, revenue is forecast to grow 168%, compared to a 95% growth forecast for the industry in Sweden. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.분석 기사 • Feb 16We Think Corline Biomedical (STO:CLBIO) Can Easily Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Reported Earnings • Nov 28Third quarter 2021 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2021 results: kr0.097 loss per share (up from kr0.13 loss in 3Q 2020). Revenue: kr2.92m (up 97% from 3Q 2020). Net loss: kr2.08m (loss narrowed 3.4% from 3Q 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 6.4%, compared to a 117% growth forecast for the industry in Sweden. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 27Second quarter 2021 earnings released: kr0.10 loss per share (vs kr0.15 loss in 2Q 2020)The company reported a decent second quarter result with reduced losses and improved control over expenses, although revenues were weaker. Second quarter 2021 results: Revenue: kr3.37m (down 11% from 2Q 2020). Net loss: kr2.15m (loss narrowed 16% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.분석 기사 • Jun 14Companies Like Corline Biomedical (STO:CLBIO) Are In A Position To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Reported Earnings • May 16First quarter 2021 earnings released: kr0.08 loss per share (vs kr0.15 loss in 1Q 2020)The company reported a decent first quarter result with reduced losses and improved control over expenses, although revenues were weaker. First quarter 2021 results: Revenue: kr2.76m (down 36% from 1Q 2020). Net loss: kr1.41m (loss narrowed 44% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 7% per year, which means it is performing significantly worse than earnings.공시 • Apr 01Corline Biomedical AB announced that it has received SEK 35.475 million in funding from M2 Asset Management AB (publ), HealthInvest Partners AB, and other investorsCorline Biomedical AB (OM:CLBIO) announced that it has issued 3,300,000 shares at issue price of SEK 10.75 per share for gross proceeds of SEK 35,475,000 on March 30, 2021. The transaction included participation from Swedish institutional investors including new investor, M2 Asset Management AB (publ) and returning investor, HealthInvest Partners AB.분석 기사 • Feb 28Here's Why We're Watching Corline Biomedical's (STO:CLBIO) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Reported Earnings • Feb 28Full year 2020 earnings released: kr0.44 loss per share (vs kr0.59 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: kr15.1m (up 27% from FY 2019). Net loss: kr7.29m (loss narrowed 24% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.Is New 90 Day High Low • Feb 15New 90-day low: kr13.80The company is down 13% from its price of kr15.95 on 17 November 2020. The Swedish market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 10.0% over the same period.Is New 90 Day High Low • Jan 13New 90-day low: kr13.85The company is down 17% from its price of kr16.65 on 14 October 2020. The Swedish market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period.공시 • Dec 19Corline Biomedical AB, Annual General Meeting, May 14, 2021Corline Biomedical AB, Annual General Meeting, May 14, 2021.Is New 90 Day High Low • Dec 01New 90-day low: kr15.10The company is down 8.0% from its price of kr16.35 on 02 September 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 7.0% over the same period.Reported Earnings • Nov 28Third quarter 2020 earnings released: kr0.13 loss per shareThe company reported a poor third quarter result with increased losses and weaker revenues and control over expenses. Third quarter 2020 results: Revenue: kr1.49m (down 31% from 3Q 2019). Net loss: kr2.15m (loss widened 11% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.공시 • Aug 30Corline Biomedical AB to Report Q4, 2020 Results on Jan 26, 2021Corline Biomedical AB announced that they will report Q4, 2020 results on Jan 26, 2021이익 및 매출 성장 예측OM:CLBIO - 애널리스트 향후 추정치 및 과거 재무 데이터 (SEK Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028143N/AN/AN/A112/31/202795N/AN/AN/A112/31/202642N/AN/A1613/31/202611-14-19-18N/A12/31/20259-15-19-18N/A9/30/20259-24-18-17N/A6/30/202510-23-21-19N/A3/31/202514-25-23-17N/A12/31/202417-23-16-9N/A9/30/202424-10-100N/A6/30/202429-6-92N/A3/31/202431-4-37N/A12/31/202336-2-101N/A9/30/202337-1-12-2N/A6/30/2023401-120N/A3/31/2023384-16-5N/A12/31/2022332-15-6N/A9/30/2022311-14-2N/A6/30/202223-3-15-6N/A3/31/202219-6-16-6N/A12/31/202117-7-14-5N/A9/30/202115-6-12-6N/A6/30/202113-6-12-7N/A3/31/202114-6-12-6N/A12/31/202015-7-14-5N/A9/30/202014-9-20-7N/A6/30/202014-9-20-9N/A3/31/202014-9-20-11N/A12/31/201912-10N/A-14N/A9/30/201911-9N/A-17N/A6/30/201911-9N/A-5N/A3/31/201910-8N/A-4N/A12/31/201810-7N/A-4N/A9/30/201817-7N/A-6N/A6/30/201816-6N/A-15N/A3/31/201815-7N/A-16N/A12/31/201716-8N/A-5N/A9/30/20177-8N/A-2N/A6/30/20179-8N/A-2N/A3/31/201710-6N/A1N/A12/31/20169-5N/A-7N/A9/30/20168-6N/A-5N/A6/30/20167-6N/A-4N/A3/31/20165-7N/A-5N/A12/31/20154-6N/A-4N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: CLBIO 의 예상 수익 증가율이 절약률(2%)보다 높은지 판단하기에는 데이터가 부족합니다.수익 vs 시장: CLBIO 의 수익이 Swedish 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.고성장 수익: CLBIO 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.수익 대 시장: CLBIO 의 수익(연간 47.3%)이 Swedish 시장(연간 -0.05%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: CLBIO 의 수익(연간 47.3%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: CLBIO의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/12 02:31종가2026/07/10 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Corline Biomedical AB는 1명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Gustaf MeyerRedeye
Price Target Changed • Feb 18Price target decreased by 12% to kr29.00Down from kr33.00, the current price target is provided by 1 analyst. New target price is 90% above last closing price of kr15.30. Stock is up 46% over the past year. The company posted a net loss per share of kr1.06 last year.
Price Target Changed • Sep 02Price target increased by 14% to kr21.00Up from kr18.50, the current price target is provided by 1 analyst. New target price is 48% above last closing price of kr14.20. Stock is up 61% over the past year. The company posted a net loss per share of kr1.06 last year.
Price Target Changed • Jun 30Price target increased by 30% to kr39.00Up from kr30.00, the current price target is provided by 1 analyst. New target price is 174% above last closing price of kr14.25. Stock is up 46% over the past year. The company is forecast to post a net loss per share of kr0.03 compared to earnings per share of kr0.11 last year.
Breakeven Date Change • May 19Forecast breakeven date pushed back to 2024The analyst covering Corline Biomedical previously expected the company to break even in 2023. New forecast suggests losses will reduce by 46% per year to 2023. The company is expected to make a profit of kr116.0m in 2024. Average annual earnings growth of 119% is required to achieve expected profit on schedule.
분석 기사 • May 11We Think Corline Biomedical (STO:CLBIO) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Reported Earnings • Apr 26Full year 2025 earnings released: kr0.59 loss per share (vs kr1.06 loss in FY 2024)Full year 2025 results: kr0.59 loss per share (improved from kr1.06 loss in FY 2024). Revenue: kr8.59m (down 50% from FY 2024). Net loss: kr14.7m (loss narrowed 37% from FY 2024). Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 106 percentage points per year, which is a significant difference in performance.
공시 • Apr 08Corline Biomedical AB, Annual General Meeting, May 12, 2026Corline Biomedical AB, Annual General Meeting, May 12, 2026, at 15:00 W. Europe Standard Time. Location: premises of advokatfirman lindahl, vaksalagatan 10, uppsala Sweden
Recent Insider Transactions • Feb 20Chief Executive Officer recently bought kr145k worth of stockOn the 17th of February, Henrik Nittmar bought around 10k shares on-market at roughly kr14.54 per share. This transaction amounted to 1.6% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Henrik has been a buyer over the last 12 months, purchasing a net total of kr377k worth in shares.
Reported Earnings • Feb 19Full year 2025 earnings released: kr0.59 loss per share (vs kr1.06 loss in FY 2024)Full year 2025 results: kr0.59 loss per share (improved from kr1.06 loss in FY 2024). Revenue: kr8.62m (down 50% from FY 2024). Net loss: kr14.7m (loss narrowed 37% from FY 2024). Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 105 percentage points per year, which is a significant difference in performance.
Price Target Changed • Feb 18Price target decreased by 12% to kr29.00Down from kr33.00, the current price target is provided by 1 analyst. New target price is 90% above last closing price of kr15.30. Stock is up 46% over the past year. The company posted a net loss per share of kr1.06 last year.
New Risk • Jan 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 19% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Revenue is less than US$1m (kr8.9m revenue, or US$963k). Minor Risks Shareholders have been diluted in the past year (19% increase in shares outstanding). Market cap is less than US$100m (kr466.2m market cap, or US$50.5m).
Reported Earnings • Nov 19Third quarter 2025 earnings released: kr0.14 loss per share (vs kr0.14 loss in 3Q 2024)Third quarter 2025 results: kr0.14 loss per share. Revenue: kr1.61m (down 41% from 3Q 2024). Net loss: kr3.36m (loss widened 12% from 3Q 2024). Revenue is forecast to grow 68% p.a. on average during the next 3 years, compared to a 27% growth forecast for the Pharmaceuticals industry in Sweden.
Price Target Changed • Sep 02Price target increased by 14% to kr21.00Up from kr18.50, the current price target is provided by 1 analyst. New target price is 48% above last closing price of kr14.20. Stock is up 61% over the past year. The company posted a net loss per share of kr1.06 last year.
Reported Earnings • Aug 27Second quarter 2025 earnings released: kr0.13 loss per share (vs kr0.20 loss in 2Q 2024)Second quarter 2025 results: kr0.13 loss per share (improved from kr0.20 loss in 2Q 2024). Revenue: kr2.63m (down 60% from 2Q 2024). Net loss: kr3.26m (loss narrowed 26% from 2Q 2024). Revenue is forecast to grow 55% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 119 percentage points per year, which is a significant difference in performance.
New Risk • Aug 04New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr23m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-kr23m free cash flow). Minor Risks Revenue is less than US$5m (kr14m revenue, or US$1.4m). Market cap is less than US$100m (kr315.9m market cap, or US$32.7m).
Reported Earnings • May 09First quarter 2025 earnings released: kr0.13 loss per share (vs kr0.078 loss in 1Q 2024)First quarter 2025 results: kr0.13 loss per share (further deteriorated from kr0.078 loss in 1Q 2024). Revenue: kr2.23m (down 60% from 1Q 2024). Net loss: kr3.07m (loss widened 84% from 1Q 2024). Revenue is forecast to grow 46% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 88 percentage points per year, which is a significant difference in performance.
공시 • Apr 10Corline Biomedical AB, Annual General Meeting, May 15, 2025Corline Biomedical AB, Annual General Meeting, May 15, 2025, at 10:00 W. Europe Standard Time. Location: at the premises of advokatfirman lindahl, vaksalagatan 10 in uppsala, uppsala Sweden
Reported Earnings • Feb 18Full year 2024 earnings: EPS and revenues miss analyst expectationsFull year 2024 results: kr1.06 loss per share (further deteriorated from kr0.084 loss in FY 2023). Revenue: kr17.7m (down 50% from FY 2023). Net loss: kr23.2m (loss widened kr21.4m from FY 2023). Revenue missed analyst estimates by 30%. Earnings per share (EPS) also missed analyst estimates. Revenue is forecast to grow 44% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.
Board Change • Feb 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Non-Executive Director Tomas Lifvendahl was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Nov 08Third quarter 2024 earnings released: kr0.14 loss per share (vs kr0.008 profit in 3Q 2023)Third quarter 2024 results: kr0.14 loss per share (down from kr0.008 profit in 3Q 2023). Revenue: kr2.76m (down 66% from 3Q 2023). Net loss: kr3.00m (down kr3.18m from profit in 3Q 2023). Revenue is forecast to grow 103% p.a. on average during the next 3 years, compared to a 32% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Aug 25Second quarter 2024 earnings released: kr0.20 loss per share (vs kr0.11 loss in 2Q 2023)Second quarter 2024 results: kr0.20 loss per share (further deteriorated from kr0.11 loss in 2Q 2023). Revenue: kr6.55m (down 24% from 2Q 2023). Net loss: kr4.37m (loss widened 82% from 2Q 2023). Revenue is forecast to grow 77% p.a. on average during the next 3 years, compared to a 39% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
분석 기사 • Aug 24Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its BusinessJust because a business does not make any money, does not mean that the stock will go down. For example, although...
Reported Earnings • May 05First quarter 2024 earnings released: kr0.078 loss per share (vs kr0.047 profit in 1Q 2023)First quarter 2024 results: kr0.078 loss per share (down from kr0.047 profit in 1Q 2023). Revenue: kr5.64m (down 45% from 1Q 2023). Net loss: kr1.67m (down 264% from profit in 1Q 2023). Revenue is forecast to grow 68% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
New Risk • May 03New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr9.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-kr9.7m free cash flow). Minor Risks Revenue is less than US$5m (kr36m revenue, or US$3.3m). Market cap is less than US$100m (kr226.7m market cap, or US$20.9m).
분석 기사 • Mar 15We Think Corline Biomedical (STO:CLBIO) Can Afford To Drive Business GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, although...
Reported Earnings • Feb 16Full year 2023 earnings released: kr0.084 loss per share (vs kr0.11 profit in FY 2022)Full year 2023 results: kr0.084 loss per share (down from kr0.11 profit in FY 2022). Revenue: kr35.9m (up 10% from FY 2022). Net loss: kr1.81m (down 178% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
공시 • Jan 31+ 1 more updateCorline Biomedical AB to Report Nine Months, 2024 Results on Nov 07, 2024Corline Biomedical AB announced that they will report nine months, 2024 results on Nov 07, 2024
공시 • Nov 03Corline Biomedical AB to Report Q1, 2024 Results on Apr 30, 2024Corline Biomedical AB announced that they will report Q1, 2024 results on Apr 30, 2024
Reported Earnings • Aug 28Second quarter 2023 earnings released: kr0.11 loss per share (vs kr0.041 profit in 2Q 2022)Second quarter 2023 results: kr0.11 loss per share (down from kr0.041 profit in 2Q 2022). Revenue: kr8.60m (up 20% from 2Q 2022). Net loss: kr2.41m (down 375% from profit in 2Q 2022). Revenue is forecast to grow 46% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
New Risk • Jul 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). High level of non-cash earnings (30% accrual ratio). Minor Risks Revenue is less than US$5m (kr38m revenue, or US$3.5m). Market cap is less than US$100m (kr306.2m market cap, or US$28.3m).
Price Target Changed • Jun 30Price target increased by 30% to kr39.00Up from kr30.00, the current price target is provided by 1 analyst. New target price is 174% above last closing price of kr14.25. Stock is up 46% over the past year. The company is forecast to post a net loss per share of kr0.03 compared to earnings per share of kr0.11 last year.
Valuation Update With 7 Day Price Move • May 05Investor sentiment improves as stock rises 31%After last week's 31% share price gain to kr13.75, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 17x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 34% over the past three years.
Reported Earnings • Apr 18Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: EPS: kr0.11 (up from kr0.34 loss in FY 2021). Revenue: kr32.6m (up 90% from FY 2021). Net income: kr2.33m (up kr9.25m from FY 2021). Profit margin: 7.1% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 12%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.
공시 • Jan 13+ 4 more updatesCorline Biomedical AB to Report First Half, 2023 Results on Aug 25, 2023Corline Biomedical AB announced that they will report first half, 2023 results on Aug 25, 2023
Reported Earnings • Nov 27Third quarter 2022 earnings released: EPS: kr0.091 (vs kr0.097 loss in 3Q 2021)Third quarter 2022 results: EPS: kr0.091 (up from kr0.097 loss in 3Q 2021). Revenue: kr11.0m (up 275% from 3Q 2021). Net income: kr1.97m (up kr4.04m from 3Q 2021). Profit margin: 18% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. Revenue is forecast to grow 97% p.a. on average during the next 3 years, compared to a 33% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
분석 기사 • Nov 26We're Interested To See How Corline Biomedical (STO:CLBIO) Uses Its Cash Hoard To GrowEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Reported Earnings • Aug 28Second quarter 2022 earnings released: EPS: kr0.041 (vs kr0.10 loss in 2Q 2021)Second quarter 2022 results: EPS: kr0.041 (up from kr0.10 loss in 2Q 2021). Revenue: kr7.31m (up 117% from 2Q 2021). Net income: kr875.0k (up kr3.03m from 2Q 2021). Profit margin: 12% (up from net loss in 2Q 2021). The move to profitability was driven by higher revenue. Over the next year, revenue is forecast to grow 39%, compared to a 90% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
분석 기사 • Jun 22Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its BusinessJust because a business does not make any money, does not mean that the stock will go down. For example, although...
Breakeven Date Change • May 19Forecast breakeven date pushed back to 2024The analyst covering Corline Biomedical previously expected the company to break even in 2023. New forecast suggests losses will reduce by 46% per year to 2023. The company is expected to make a profit of kr116.0m in 2024. Average annual earnings growth of 119% is required to achieve expected profit on schedule.
Reported Earnings • May 16First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: kr0.04 loss per share (up from kr0.08 loss in 1Q 2021). Revenue: kr4.53m (up 65% from 1Q 2021). Net loss: kr852.0k (loss narrowed 39% from 1Q 2021). Revenue exceeded analyst estimates by 41%. Earnings per share (EPS) also surpassed analyst estimates by 15%. Over the next year, revenue is forecast to grow 168%, compared to a 95% growth forecast for the industry in Sweden. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
분석 기사 • Feb 16We Think Corline Biomedical (STO:CLBIO) Can Easily Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Reported Earnings • Nov 28Third quarter 2021 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2021 results: kr0.097 loss per share (up from kr0.13 loss in 3Q 2020). Revenue: kr2.92m (up 97% from 3Q 2020). Net loss: kr2.08m (loss narrowed 3.4% from 3Q 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 6.4%, compared to a 117% growth forecast for the industry in Sweden. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 27Second quarter 2021 earnings released: kr0.10 loss per share (vs kr0.15 loss in 2Q 2020)The company reported a decent second quarter result with reduced losses and improved control over expenses, although revenues were weaker. Second quarter 2021 results: Revenue: kr3.37m (down 11% from 2Q 2020). Net loss: kr2.15m (loss narrowed 16% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
분석 기사 • Jun 14Companies Like Corline Biomedical (STO:CLBIO) Are In A Position To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Reported Earnings • May 16First quarter 2021 earnings released: kr0.08 loss per share (vs kr0.15 loss in 1Q 2020)The company reported a decent first quarter result with reduced losses and improved control over expenses, although revenues were weaker. First quarter 2021 results: Revenue: kr2.76m (down 36% from 1Q 2020). Net loss: kr1.41m (loss narrowed 44% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 7% per year, which means it is performing significantly worse than earnings.
공시 • Apr 01Corline Biomedical AB announced that it has received SEK 35.475 million in funding from M2 Asset Management AB (publ), HealthInvest Partners AB, and other investorsCorline Biomedical AB (OM:CLBIO) announced that it has issued 3,300,000 shares at issue price of SEK 10.75 per share for gross proceeds of SEK 35,475,000 on March 30, 2021. The transaction included participation from Swedish institutional investors including new investor, M2 Asset Management AB (publ) and returning investor, HealthInvest Partners AB.
분석 기사 • Feb 28Here's Why We're Watching Corline Biomedical's (STO:CLBIO) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Reported Earnings • Feb 28Full year 2020 earnings released: kr0.44 loss per share (vs kr0.59 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: kr15.1m (up 27% from FY 2019). Net loss: kr7.29m (loss narrowed 24% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.
Is New 90 Day High Low • Feb 15New 90-day low: kr13.80The company is down 13% from its price of kr15.95 on 17 November 2020. The Swedish market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 10.0% over the same period.
Is New 90 Day High Low • Jan 13New 90-day low: kr13.85The company is down 17% from its price of kr16.65 on 14 October 2020. The Swedish market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period.
공시 • Dec 19Corline Biomedical AB, Annual General Meeting, May 14, 2021Corline Biomedical AB, Annual General Meeting, May 14, 2021.
Is New 90 Day High Low • Dec 01New 90-day low: kr15.10The company is down 8.0% from its price of kr16.35 on 02 September 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 7.0% over the same period.
Reported Earnings • Nov 28Third quarter 2020 earnings released: kr0.13 loss per shareThe company reported a poor third quarter result with increased losses and weaker revenues and control over expenses. Third quarter 2020 results: Revenue: kr1.49m (down 31% from 3Q 2019). Net loss: kr2.15m (loss widened 11% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.
공시 • Aug 30Corline Biomedical AB to Report Q4, 2020 Results on Jan 26, 2021Corline Biomedical AB announced that they will report Q4, 2020 results on Jan 26, 2021